| Business

Become a contributor

Bookmark Econotimes

| Business

SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off

CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences

Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing

Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil

Washington Post Publisher Will Lewis Steps Down After Layoffs

SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates

Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links

TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering

Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies

FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns

Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks

Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

Ford and Geely Explore Strategic Manufacturing Partnership in Europe

©Econometrics LLC . All Rights Reserved.

Zogenix to Participate in Oppenheimer Life Sciences Summit 2016

Tuesday, November 22, 2016 1:00 PM UTC

EMERYVILLE, Calif., Nov. 22, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Gail Farfel, Ph.D., Chief Development Officer, will participate in the Oppenheimer Life Sciences Summit 2016, being held at the Sofitel New York Hotel on Tuesday, November 29^th.

About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT: 	
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate

Trump Says “Very Good Talks” Underway on Russia-Ukraine War as Peace Efforts Continue

Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran

New York Legalizes Medical Aid in Dying for Terminally Ill Patients

China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices

Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility

SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates

Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Zogenix to Participate in Oppenheimer Life Sciences Summit 2016

Editor's Picks

Welcome to EconoTimes